DE60043708D1 - Verfahren zur erhaltung zellimmuneantworten gegen proteinen - Google Patents
Verfahren zur erhaltung zellimmuneantworten gegen proteinenInfo
- Publication number
- DE60043708D1 DE60043708D1 DE60043708T DE60043708T DE60043708D1 DE 60043708 D1 DE60043708 D1 DE 60043708D1 DE 60043708 T DE60043708 T DE 60043708T DE 60043708 T DE60043708 T DE 60043708T DE 60043708 D1 DE60043708 D1 DE 60043708D1
- Authority
- DE
- Germany
- Prior art keywords
- immune responses
- responses against
- cell immune
- maintaining cell
- against proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 2
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/918—Immunological
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15929899P | 1999-10-13 | 1999-10-13 | |
PCT/US2000/028040 WO2001026681A2 (en) | 1999-10-13 | 2000-10-10 | Method of obtaining cellular immune responses from proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60043708D1 true DE60043708D1 (de) | 2010-03-04 |
Family
ID=22571953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60043708T Expired - Lifetime DE60043708D1 (de) | 1999-10-13 | 2000-10-10 | Verfahren zur erhaltung zellimmuneantworten gegen proteinen |
Country Status (10)
Country | Link |
---|---|
US (2) | US6534064B1 (de) |
EP (1) | EP1221968B1 (de) |
JP (2) | JP2003511420A (de) |
AT (1) | ATE454901T1 (de) |
AU (1) | AU7877900A (de) |
CA (1) | CA2388676A1 (de) |
DE (1) | DE60043708D1 (de) |
ES (1) | ES2337017T3 (de) |
PT (1) | PT1221968E (de) |
WO (1) | WO2001026681A2 (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7141244B1 (en) * | 1992-03-02 | 2006-11-28 | Chiron Srl | Helicobacter pylori proteins useful for vaccines and diagnostics |
GB2324093A (en) * | 1996-01-04 | 1998-10-14 | Rican Limited | Helicobacter pylori bacterioferritin |
US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
GB9807721D0 (en) * | 1998-04-08 | 1998-06-10 | Chiron Spa | Antigen |
CA2358385C (en) | 1998-12-31 | 2013-08-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
EP1221968B1 (de) * | 1999-10-13 | 2010-01-13 | Novartis Vaccines and Diagnostics, Inc. | Verfahren zur erhaltung zellimmuneantworten gegen proteinen |
WO2002038175A1 (en) * | 2000-11-07 | 2002-05-16 | Immunovaccine Technologies Inc. | Vaccines with enhanced immune response and methods for their preparation |
WO2002080982A2 (en) * | 2001-01-12 | 2002-10-17 | Chiron Corporation | Nucleic acid mucosal immunization |
GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
ITRM20010336A1 (it) * | 2001-06-13 | 2002-12-13 | Biostrands S R L | Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi |
CA2489019A1 (en) * | 2001-06-15 | 2002-12-27 | Nordic Vaccine Technology A/S | Therapeutical vaccination |
US20030138458A1 (en) * | 2001-06-29 | 2003-07-24 | Michael Houghton | HCV E1E2 vaccine compositions |
EP1411770A4 (de) | 2001-07-05 | 2006-05-10 | Chiron Corp | Polynukleotide, die für antigene hiv-polypeptide des c-typs codieren, polypeptide und ihre verwendung |
JP2005506322A (ja) * | 2001-08-31 | 2005-03-03 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Helicobacterpyloriワクチン接種 |
ATE447967T1 (de) | 2001-09-14 | 2009-11-15 | Cytos Biotechnology Ag | Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung |
JP2005519619A (ja) * | 2002-03-13 | 2005-07-07 | 麒麟麦酒株式会社 | インフルエンザm2タンパク質に対するヒトモノクローナル抗体および上記抗体を作製しかつ利用する方法 |
EP1490083A1 (de) | 2002-03-29 | 2004-12-29 | The Regents of the University of California | Mikrogelteilchen zur abgabe von biologisch wirksamen materialien |
JP2004099584A (ja) * | 2002-05-02 | 2004-04-02 | Keio Gijuku | Hsvを用いた抗腫瘍剤 |
EP1585542B1 (de) | 2002-12-27 | 2012-06-13 | Novartis Vaccines and Diagnostics, Inc. | Immunogene zusammensetzungen enthaltend phospholipid |
JP2007524609A (ja) * | 2003-04-10 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | コンフォメーションに関する変種のプロファイリング、抗体組成物 |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
FR2859909B1 (fr) | 2003-09-22 | 2007-09-07 | Biomerieux Sa | Procede de preparation de microparticules bioresorbables, microparticules obtenues et utilisation |
AU2006252406B2 (en) | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
CA2626257A1 (en) * | 2005-10-17 | 2007-04-26 | Novartis Ag | Multiclade hiv vaccines |
EP1973608A1 (de) | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunstimulatorische nukleinsäure-packteilchen zur behandlung von überempfindlichkeit |
CA2655108C (en) | 2006-06-12 | 2019-05-07 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
CA2659529C (en) | 2006-07-21 | 2016-11-01 | California Institute Of Technology | Targeted gene delivery for dendritic cell vaccination |
EP2125854B1 (de) | 2006-12-12 | 2016-10-26 | Kuros Biosciences AG | Oligonukleotide mit hohen konzentrationen an guaninmonomeren |
CN106310293A (zh) * | 2007-09-27 | 2017-01-11 | 免疫疫苗技术有限公司 | 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用 |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
US8815253B2 (en) | 2007-12-07 | 2014-08-26 | Novartis Ag | Compositions for inducing immune responses |
EP2296696B1 (de) | 2008-06-05 | 2014-08-27 | ImmunoVaccine Technologies Inc. | Zusammensetzungen mit liposomen, einem antigen, einem polynucleotid und einem träger mit einer kontinuierlichen phase einer hydrophoben substanz |
WO2010009291A1 (en) * | 2008-07-16 | 2010-01-21 | Surmodics Pharmaceuticals, Inc. | Process for preparing microparticles containing bioactive peptides |
PT2456786E (pt) | 2009-07-24 | 2014-03-25 | Immune Design Corp | Vetores lentivirais pseudotipados com uma glicoproteína do envelope do vírus sindbis |
EP2550362B1 (de) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv-glycoproteine und rekombinante vektoren |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
CN113876945A (zh) | 2011-10-06 | 2022-01-04 | 免疫疫苗技术有限公司 | 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用 |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
KR102070472B1 (ko) | 2012-03-30 | 2020-01-29 | 이뮨 디자인 코포레이션 | Dc-사인을 발현하는 세포에 대해 개선된 형질도입 효능을 갖는 렌티바이러스 벡터 입자 |
US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
US20130302366A1 (en) * | 2012-05-09 | 2013-11-14 | Christopher Marshall | Conformationally Specific Viral Immunogens |
EP2679596B1 (de) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 Env-proteinvariante |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (de) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3069730A3 (de) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3072901A1 (de) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
KR20240023684A (ko) | 2016-09-13 | 2024-02-22 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
WO2018055535A2 (en) | 2016-09-21 | 2018-03-29 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2750045A1 (de) * | 1977-11-09 | 1979-05-10 | Behringwerke Ag | Verfahren zur entfernung von detergentien aus virusantigensuspensionen |
US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
JPS62138500A (ja) * | 1985-12-11 | 1987-06-22 | Sumitomo Pharmaceut Co Ltd | ポリペプチドの製法 |
JPH01500999A (ja) * | 1986-10-20 | 1989-04-06 | チロン コーポレイション | Hsvの治療的処置に用いるワクチン |
JPH0751513B2 (ja) * | 1988-04-28 | 1995-06-05 | 国立予防衛生研究所長 | A型肝炎ワクチン |
CA2037151A1 (en) * | 1990-03-23 | 1991-09-24 | F. Hoffmann-La Roche Ag | Plasmodium sporozoite antigen |
WO1993020840A1 (en) * | 1992-04-14 | 1993-10-28 | British Bio-Technology Limited | Induction of ctl responses |
CA2153391C (en) * | 1993-01-11 | 2000-08-15 | Kenneth Rock | Inducing cytotoxic t lymphocyte responses |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5709995A (en) * | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
US5955342A (en) * | 1994-08-15 | 1999-09-21 | Connaught Laboratories Limited | Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region |
US5851826A (en) * | 1995-07-26 | 1998-12-22 | Children's Medical Center Corporation | Helper virus-free herpesvirus vector packaging system |
ZA982763B (en) * | 1997-04-09 | 1998-10-05 | Akzo Nobel Nv | Vaccines |
AU750702B2 (en) | 1997-05-01 | 2002-07-25 | Chiron Corporation | Use of virus-like particles as adjuvants |
EP0913479A3 (de) * | 1997-10-27 | 2000-10-25 | Smithkline Beecham Corporation | Adenin Glycosylase |
EP1042001B1 (de) * | 1997-12-16 | 2002-04-03 | Chiron Corporation | Verwendung von mikropartikeln mit submikron öl/wasser emulsionen |
DE69922958T3 (de) * | 1998-06-24 | 2008-06-26 | Innogenetics N.V. | Hcv hüllproteine partikel : verwendung für therapeutische impfung |
EP1221968B1 (de) * | 1999-10-13 | 2010-01-13 | Novartis Vaccines and Diagnostics, Inc. | Verfahren zur erhaltung zellimmuneantworten gegen proteinen |
-
2000
- 2000-10-10 EP EP00968937A patent/EP1221968B1/de not_active Expired - Lifetime
- 2000-10-10 US US09/686,345 patent/US6534064B1/en not_active Expired - Lifetime
- 2000-10-10 WO PCT/US2000/028040 patent/WO2001026681A2/en active Application Filing
- 2000-10-10 JP JP2001529742A patent/JP2003511420A/ja not_active Withdrawn
- 2000-10-10 DE DE60043708T patent/DE60043708D1/de not_active Expired - Lifetime
- 2000-10-10 PT PT00968937T patent/PT1221968E/pt unknown
- 2000-10-10 ES ES00968937T patent/ES2337017T3/es not_active Expired - Lifetime
- 2000-10-10 AT AT00968937T patent/ATE454901T1/de active
- 2000-10-10 AU AU78779/00A patent/AU7877900A/en not_active Abandoned
- 2000-10-10 CA CA002388676A patent/CA2388676A1/en not_active Abandoned
-
2003
- 2003-01-08 US US10/340,034 patent/US7604802B2/en not_active Expired - Fee Related
-
2011
- 2011-03-22 JP JP2011063393A patent/JP2011116796A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20030104067A1 (en) | 2003-06-05 |
EP1221968B1 (de) | 2010-01-13 |
JP2011116796A (ja) | 2011-06-16 |
US7604802B2 (en) | 2009-10-20 |
JP2003511420A (ja) | 2003-03-25 |
US6534064B1 (en) | 2003-03-18 |
WO2001026681A3 (en) | 2002-01-31 |
AU7877900A (en) | 2001-04-23 |
WO2001026681A2 (en) | 2001-04-19 |
ATE454901T1 (de) | 2010-01-15 |
EP1221968A2 (de) | 2002-07-17 |
ES2337017T3 (es) | 2010-04-20 |
CA2388676A1 (en) | 2001-04-19 |
PT1221968E (pt) | 2010-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60043708D1 (de) | Verfahren zur erhaltung zellimmuneantworten gegen proteinen | |
PL401469A1 (pl) | Pochodna azabicykliczna, sposób jej wytwarzania, jej zastosowanie w medycynie oraz zawierajaca pochodna kompozycja | |
ATA1292000A (de) | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen | |
WO2001034801A3 (en) | Recombinant gelatin in vaccines | |
AU2903999A (en) | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines | |
IL132468A0 (en) | A kit for inducing immune response against a tumor or a disease caused by an infection agent | |
AU2001265346A1 (en) | Artificial antigen presenting cells and methods of use thereof | |
EE05212B1 (et) | Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i | |
NZ527283A (en) | Modified antibodies and methods of use | |
DK0757717T3 (da) | Papillomavirusvacciner | |
DE69332820T2 (de) | Impfstoff gegen den hepatitis e-virus und verfahren | |
DE69930630D1 (de) | B2microglobulin fusionsproteine und varianten mit hoher affinität | |
WO2002088328A3 (en) | Method for generating highly active human dendritic cells from monocytes | |
ATE460943T1 (de) | Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren | |
DE69933875D1 (de) | Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt. | |
EP2193804A3 (de) | Rekombinantes Adenylat-Cyclase-Toxin von Bordetella induziert T-Zell-Antworten gegen tumorale Antigene | |
YU40796A (sh) | Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije | |
ATE310750T1 (de) | Verotoxin b untereinheit zur immunisierunug | |
DE602004015141D1 (de) | Modifizierte ganzzell-, zellextrakt- und omv-basierte impfstoffe | |
AU7546500A (en) | Designing immunogens | |
EP1131338A4 (de) | Methode für die herstellung von gereinigtem invasinprotein und seine anwendung | |
ATE385809T1 (de) | Saponin-zusammensetzungen und deren verwendung | |
DE602004019141D1 (de) | Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide | |
AU2002221553A1 (en) | Vaccines containing recombinant hantavirus proteins, methods for producing said vaccines and their use | |
DE59704883D1 (de) | Komplex aus antigen und zellbestandteil, verfahren zur dessen herstellung und therapeutische verwendungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |